
Keywords: AB; amyloid beta; AD; Alzheimer's disease; AGE; advanced glycation end products; AKT; protein kinase B; BAD; Bcl 2 antagonist of death; BBB; blood brain barrier; Bcl-2; B-cell lymphoma 2; Bcl-XL; B-cell lymphoma extra large; Bim; Bcl-2 interacting media